James Lantz
Internal Medicine · Douglasville, GANPI 1881667822
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 585 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,156 and has fallen 99.0% since, to $22 in 2025. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 585 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- Amgen$928
- Amarin Pharma, Inc.$798
- Lilly USA, LLC$697
- Bayer$540
- plus $4K from 35 others
What the payments were for
- Food & beverage$10,150100%
- Education$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,181 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 22 | $21,695 |
| MounjaroTirzepatide | 16 | $14,138 |
| JardianceEmpagliflozin | 14 | $14,131 |
| FarxigaDapagliflozin Propanediol | 11 | $10,934 |
| EliquisApixaban | 14 | $10,312 |
| Rosuvastatin Calcium | 45 | $572 |
| Atorvastatin Calcium | 61 | $543 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $479 |
| Olmesartan Medoxomil | 22 | $461 |
| Pantoprazole Sodium | 33 | $456 |
| Levothyroxine Sodium | 46 | $385 |
| Losartan Potassium | 41 | $372 |
| Amlodipine Besylate | 99 | $371 |
| Fluticasone Propionate | 21 | $352 |
| Duloxetine Hcl | 20 | $331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,536 | $21,69522 claims |
| Lilly USA, LLCMounjaro | $697 | $14,13816 claims |
| Boehringer IngelheimJardiance | $395 | $14,13114 claims |
| AstraZenecaFarxiga | $1,465 | $10,93411 claims |
| PfizerEliquis | $316 | $10,31214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Douglasville
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.